EGFR and glioblastoma: The use of the EGFR tyrosine kinase inhibitors erlotinib and gefitinib have been evaluated in numerous clinical trials, alone and in combination with standard glioblastoma treatment, with minimal effect on patient survival [35,36,37,38].